Christine Poon, a director of Regeneron Pharmaceuticals, Inc., filed a Form 144 notice of proposed sale on November 2, 2026, covering 7,830 shares of Regeneron common stock with an aggregate market value of $7,526,665.80.

Key Highlights

  • Seller and role: Christine Poon, listed as a Director of Regeneron Pharmaceuticals, Inc.
  • Shares proposed for sale: 7,830 shares of Regeneron common stock, with an aggregate market value of $7,526,665.80.
  • Broker: Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282, is named as the broker for the proposed sale.
  • Approximate date of sale: November 2, 2026, on the NASD exchange, according to the filing.
  • Shares outstanding: 101,630,713 shares of Regeneron common stock were reported outstanding at the time of the filing.
  • Acquisition history: The securities were acquired as compensation through stock options from the issuer in three tranches of 2,610 shares each, on January 3, 2018, January 3, 2019, and January 3, 2020.
  • Prior sales: The filing reported nothing to report under securities sold during the past 3 months.

Director Christine Poon's Proposed Sale of Regeneron Stock via Rule 144

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Christine Poon, a director of Regeneron Pharmaceuticals, Inc. (issuer SEC file number 000-19034), has provided notice of a proposed sale of 7,830 shares of Regeneron common stock. The aggregate market value of the shares proposed for sale is listed as $7,526,665.80, and the approximate date of sale is given as November 2, 2026. The filing was signed by Goldman Sachs & Co. LLC on behalf of Christine Poon.

The filing discloses that the securities to be sold were acquired through three separate stock option transactions, each described as "Acquired as compensation -- Stock Options" from the issuer. Each tranche consisted of 2,610 shares, acquired on January 3, 2018, January 3, 2019, and January 3, 2020, respectively. The nature of payment for all three tranches is described in the filing as "Compensation -- Cashless exercise / same-day sale." No securities of Regeneron were reported as sold by Poon during the three months preceding this notice.

The filing states that the person for whose account the securities are to be sold represents, by signing, "that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." Regeneron Pharmaceuticals, Inc. is headquartered at 777 Old Saw Mill River Road, Tarrytown, New York 10591, according to the filing.

What Was Disclosed

A Form 144 notice filed November 2, 2026 disclosed that Regeneron director Christine Poon proposed to sell 7,830 shares of common stock with an aggregate market value of $7,526,665.80, acquired via stock options granted by the issuer in 2018, 2019, and 2020.